April 24, 2026 FDA Form 483 for Zhejiang Huahai Pharmaceutical Co., Ltd. — 1 Citations

Observation 1 — -- 1 of 24 -- -- 2 of 24 -- -- 3 of 24 -- -- 4 of 24 -- -- 5 of 24 -- -- 6 of 24 -- -- 7

-- 1 of 24 -- -- 2 of 24 -- -- 3 of 24 -- -- 4 of 24 -- -- 5 of 24 -- -- 6 of 24 -- -- 7 of 24 -- -- 8 of 24 -- -- 9 of 24 -- -- 10 of 24 -- -- 11 of 24 -- -- 12 of 24 -- -- 13 of 24 -- -- 14 of 24 -- -- 15 of 24 -- -- 16 of 24 -- -- 17 of 24 -- -- 18 of 24 -- -- 19 of 24 -- -- 20 of 24 -- -- 21 of 24 -- -- 22 of 24 -- -- 23 of 24 -- -- 24 of 24 -- A Form FDA 483 is issued at the close of an FDA facility inspection to list conditions an investigator observed that may violate the Federal Food, Drug, and Cosmetic Act or its implementing regulations. It reflects the investigator's professional judgment at that point in time and is not a final agency determination, an enforcement action, or proof that a violation occurred. Firms are expected to respond in writing, typically within 15 business days, describing the corrective and preventive actions they plan to take. FDA reviews that response, along with any follow-up evidence, before deciding what happens next. Many 483s are resolved through corrective action alone. When FDA judges a firm's response inadequate, or when the underlying conditions are serious enough, the observations documented here can lead to a Warning Letter or further regulatory action. This page presents the observations exactly as recorded on the FDA-issued document; always confirm citation language against the original record before relying on it. A Form FDA 483 is issued at the close of an FDA facility inspection to list conditions an investigator observed that may violate the Federal Food, Drug, and Cosmetic Act or its implementing regulations. It reflects the investigator's professional judgment at that point in time and is not a final agency determination, an enforcement action, or proof that a violation occurred. Firms are expected to respond in writing, typically within 15 business days, describing the corrective and preventive actions they plan to take. FDA reviews that response, along with any follow-up evidence, before deciding what happens next. Many 483s are resolved through corrective action alone. When FDA judges a firm's response inadequate, or when the underlying conditions are serious enough, the observations documented here can lead to a Warning Letter or further regulatory action. This page presents the observations exactly as recorded on the FDA-issued document; always confirm citation language against the original record before relying on it.